Local treatment of neurofibromas
Inventors
Chen, Ruihong • Rubenstein, Allan E. • Shen, Xiaodong • Stewart, Scott • Yu, Jin-Chen
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8487004-B2
Publication Date
2013-07-16
Expiration Date
Abstract
A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.
Core Innovation
The invention provides a method of treating a dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma in a subject in need of such treatment by locally administering a composition to the region of the tumor. The composition comprises one non-carcinogenic agent for treating the neurofibroma on the subject, and the non-carcinogenic agent is a non-steroidal anti-inflammatory (NSAID) agent.
The locally administered composition optionally comprises a pharmaceutically acceptable excipient that aids in transporting the non-carcinogenic agent into the tumor. The excipient is used so that the non-carcinogenic agent is maintained for a sufficient period of time to treat the neurofibroma, and the excipient may comprise a skin penetrant.
The local administration is described as topical application to the surface of the skin over the tumor region or intralesional injection into the tumor. The patent further identifies diclofenac as the NSAID agent in a dependent claim context.
Claims Coverage
The patent includes one independent claim with dependent refinements that specify administration route, excipient composition, and diclofenac. The inventive coverage centers on 5 inventive features.
Local tumor-region administration of non-carcinogenic NSAID composition for neurofibroma
Treating a dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma by locally administering a composition to the region of the tumor, wherein the composition comprises one non-carcinogenic agent for treating the neurofibroma and the non-carcinogenic agent is a non-steroidal anti-inflammatory (NSAID) agent.
Topical skin application over the tumor region with excipient-assisted transport
Local administration by topical application to the surface of the skin over the tumor region, where the excipient aids transport across skin to the tumor and maintains the agent on the subject’s skin.
Intralesional injection into the tumor
Local administration by intralesionally injecting the composition into the tumor.
Excipient comprising a skin penetrant
The excipient comprises a skin penetrant.
Using diclofenac as the NSAID agent
The NSAID agent is diclofenac.
Overall claim coverage centers on locally administering to the tumor region a composition containing a non-carcinogenic NSAID agent, optionally with an excipient to aid transport into the tumor and maintain the agent for sufficient time, with dependent features refining topical versus intralesional delivery, excipient skin-penetrant content, and diclofenac.
Stated Advantages
Transporting the non-carcinogenic agent into the tumor and preferably maintaining the agent for a sufficient period of time to treat the neurofibroma.
Documented Applications
Assay-driven selection of candidate agents for treating neurofibromas using a cell proliferation panel of NF1-related lines, a dermal neurofibroma explant assay, and a DNF xenograft model.
Treatment of dermal neurofibroma, subdermal neurofibroma, and superficial plexiform neurofibroma in a subject by locally administering a tumor-region composition.
Interested in licensing this patent?